Sobi, a biopharmaceutical company headquartered in Sweden, announced that it will launch its new drugs for treating rare diseases, including primary hemophagocytic lymphohistiocytosis (HLH), immune thrombocytopenia (ITP), and alkaptonuria (AKU), in Korea. Sobi and Handok have entered into a business agreement to launch in Korea.

According to the pharmaceutical industry, on the 14th, Swedish Orphan Biovitrum (Sobi) decided to establish a local joint venture with Handok. The duo has announced plans to set up a firm in the first half of this year and to launch treatments for rare diseases in Korea. Sobi, a global biopharmaceutical company headquartered in Sweden, specializes in rare diseases and provides inno